Evidence map›Paper›PMID 40242551›Full record

ReviewFundamental research2025

Plant-derived nanovesicles: Promising therapeutics and drug delivery nanoplatforms for brain disorders.

Ruoning Wang, Yingjie Zhang, Yumiao Guo, Wei Zeng, Jinge Li, Jie Wu, Nengjin Li, Anran Zhu, Jiale Li, Liuqing Di and 1 more

Abstract readReview
In one paragraph

Review in Fundamental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Green nanomedicine for cancer therapy.Chinese medical journal · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Hydroxypropyl methylcellulose stearoxy ether hydrogel loaded withFrontiers in bioengineering and biotechnology · 2026
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruoning WangSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yingjie ZhangSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yumiao GuoSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Wei ZengSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jinge LiSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jie WuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Nengjin LiSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Anran ZhuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jiale LiSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Liuqing DiSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Peng CaoSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plant-derived nanovesicles (PDNVs), including plant extracellular vesicles (EVs) and plant exosome-like nanovesicles (ELNs), are natural nano-sized membranous vesicles containing bioactive molecules. PDNVs consist of a bilayer of lipids that can effectively encapsulate hydrophilic and lipophilic drugs, improving drug stability and solubility as well as providing increased bioavailability, reduced systemic toxicity, and enhanced target accumulation. Bioengineering strategies can also be exploited to modify the PDNVs to achieve precise targeting, controlled drug release, and massive production. Meanwhile, they are capable of crossing the blood-brain barrier (BBB) to transport the cargo to the lesion sites without harboring human pathogens, making them excellent therapeutic agents and drug delivery nanoplatform candidates for brain diseases. Herein, this article provides an initial exposition on the fundamental characteristics of PDNVs, including biogenesis, uptake process, isolation, purification, characterization methods, and source. Additionally, it sheds light on the investigation of PDNVs' utilization in brain diseases while also presenting novel perspectives on the obstacles and clinical advancements associated with PDNVs.

Indexed as

Brain disordersDrug delivery platformsEdible plantsPlant-derived nanovesiclesTraditional Chinese medicine

Identifiers

PMID40242551
PMCPMC11997602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.